We are live on ! Find out more

Viridian Therapeutics

VRDN

Market cap $2.74B

24.18 USD

+0.16

0.67%

At close Updated Aug 25, 4:00 PM EDT

Pre-market

After hours

24.18

0.00

0%

1 day

0.67%

5 days

-1.39%

1 month

22.74%

3 months

42.24%

6 months

-16.45%

Year to date

-21.19%

1 year

30.21%

5 years

73.96%

10 years

-80.17%

About: Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.

Employees: 252

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 33.3%

Neutral 66.7%

Negative 0%

Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today reported recent business highlights and financial results for the second quarter ended June 30, 2026. “We are very encouraged by the early indications from our recent launch of Lumvoa as we start a new chapter for Viridian as a commercial-stage company,” said Steve.

Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results

Zacks Investment Research

VRDN Stock Rises 6.3% in a Week: Here's What You Need to Know

Viridian enters the commercial stage after FDA approval of Lumvoa for thyroid eye disease, with expanded labeling and plans for an immediate U.S. launch.

VRDN Stock Rises 6.3% in a Week: Here's What You Need to Know

Viridian Therapeutics: Lumvoa Ready For Prime Time Following FDA Approval

Viridian Therapeutics received early FDA approval for Lumvoa, offering a label advantage over Amgen's Tepezza in thyroid eye disease. Lumvoa's shorter infusion course, inclusion of chronic TED data, and immediate availability position VRDN for commercial success, though management is tempering near-term revenue expectations. Elegrobart's underwhelming REVEAL-1 phase 3 results limit its competitive edge in active TED but highlight its convenience and potential in underpenetrated chronic TED based on REVEAL-2 study results.

Viridian Therapeutics: Lumvoa Ready For Prime Time Following FDA Approval

Viridian Therapeutics, Inc. (VRDN) Discusses FDA Approval and Launch Plans for Lumvoa as a New Therapy for Thyroid Eye Disease Transcript

Viridian Therapeutics, Inc. (VRDN) Discusses FDA Approval and Launch Plans for Lumvoa as a New Therapy for Thyroid Eye Disease Transcript

Viridian Therapeutics, Inc. (VRDN) Discusses FDA Approval and Launch Plans for Lumvoa as a New Therapy for Thyroid Eye Disease Transcript

Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease

The U.S. Food and Drug Administration on Friday approved Viridian Therapeutics Inc.'s (NASDAQ:VRDN) new thyroid eye disease (TED) treatment, Lumvoa (veligrotug-vvze).

Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease

Concentrix, AeroVironment And 3 Stocks To Watch Heading Into Monday

With U.S. stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:

Concentrix, AeroVironment And 3 Stocks To Watch Heading Into Monday

Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Lumvoa™ (veligrotug-vvze) for the treatment of thyroid eye disease (TED). TED is a rare, debilitating autoimmune disease characterized by inflammation and tissue remodeling around and behind the.

Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease

Viridian Therapeutics: A Two-Step TED Franchise With More Leverage Than The Market Appreciates

Viridian Therapeutics is positioned to transition from late-stage biotech to commercial rare disease player with its TED franchise. Veligrotug's pivotal Phase 3 data in active and chronic TED and an FDA PDUFA date of June 30, 2026, create a near-term commercial entry point. Elegrobart, a subcutaneous follow-on asset, targets market expansion by reducing treatment barriers and is planned for a Q1 2027 BLA submission.

Viridian Therapeutics: A Two-Step TED Franchise With More Leverage Than The Market Appreciates

Viridian Therapeutics, Inc. (VRDN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Viridian Therapeutics, Inc. (VRDN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Viridian Therapeutics, Inc. (VRDN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Viridian Metals Commences 2026 Diamond Drill Program at the Kraken

OTTAWA, June 09, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) (“Viridian” or the “Company”) announces that diamond drilling has commenced at its Kraken Copper-Nickel-Cobalt Project in Labrador, with the first drill now turning on the initial hole of the Company's fully funded 2026 exploration program. The 2026 program is expected to consist of 50 diamond drill holes designed to systematically infill between widely spaced drill holes completed along the five-kilometre-long Main Zone conductive corridor, where mineralization has been intersected in holes spaced up to one kilometre apart.

Viridian Metals Commences 2026 Diamond Drill Program at the Kraken

See News Rankings

Price charts implemented using Lightweight Charts™